Research & Literature

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Patnaik MM, Wassie EA, Padron E, et al.

Blood cancer journal 2015; (5()):e270 doi:10.1038/bcj.2014.90.

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.

McCullough KB, Patnaik MM

Current hematologic malignancy reports 2015; (10(3)):292-302 doi:10.1007/s11899-015-0271-4.

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Symeonidis A, van Biezen A, de Wreede L, et al.

British journal of haematology 2015; (171(2)):239-246 doi:10.1111/bjh.13576.

Age-related mutations and chronic myelomonocytic leukemia.

Mason CC, Khorashad JS, Tantravahi SK, et al.

Leukemia 2016; (30(4)):906-13 doi:10.1038/leu.2015.337.

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.

Patnaik MM, Tefferi A

Blood cancer journal 2016; (6()):e393 doi:10.1038/bcj.2016.5.

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Padron E, Dezern A, Andrade-Campos M, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(15)):3746-54 doi:10.1158/1078-0432.CCR-15-2781.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

Merlevede J, Droin N, Qin T, et al.

Nature communications 2016; (7()):10767 doi:10.1038/ncomms10767.

Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.

Grignano E, Mekinian A, Braun T, et al.

Leukemia research 2016; (47()):136-41.

Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus.

Moura CA, Santiago M, Neto J, et al.

Lupus 2017; (26(2)):204-207 doi:10.1177/0961203316657436.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Elena C, Gallì A, Such E, et al.

Blood 2016; (128(10)):1408-17 doi:10.1182/blood-2016-05-714030.

Genomic determinants of chronic myelomonocytic leukemia.

Patel BJ, Przychodzen B, Thota S, et al.

Leukemia 2017; (31(12)):2815-2823 doi:10.1038/leu.2017.164.

How I treat chronic myelomonocytic leukemia.

Solary E, Itzykson R

Blood 2017; (130(2)):126-136 doi:10.1182/blood-2017-04-736421.

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Santini V, Allione B, Zini G, et al.

Leukemia 2018; (32(2)):413-418 doi:10.1038/leu.2017.186.

Tet2 restrains inflammatory gene expression in macrophages.

Cull AH, Snetsinger B, Buckstein R, et al.

Experimental hematology 2017; (55()):56-70.e13 doi:10.1016/j.exphem.2017.08.001.

Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.

Loghavi S, Curry JL, Garcia-Manero G, et al.

Journal of cutaneous pathology 2017; (44(12)):1075-1079 doi:10.1111/cup.13039.

The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study.

Choi MH, Choe YH, Park Y, et al.

Transfusion 2018; (58(1)):208-216 doi:10.1111/trf.14329.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

Assi R, Kantarjian HM, Garcia-Manero G, et al.

American journal of hematology 2018; (93(2)):277-285 doi:10.1002/ajh.24972.

Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia.

Picot T, Aanei CM, Flandrin Gresta P, et al.

Frontiers in oncology 2018; (8()):109 doi:10.3389/fonc.2018.00109.

Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Patnaik MM, Tefferi A

American journal of hematology 2018; (93(6)):824-840 doi:10.1002/ajh.25104.

Are psychological interventions effective on anxiety in cancer patients? A systematic review and meta-analyses.

Sanjida S, McPhail SM, Shaw J, et al.

Psycho-oncology 2018; (27(9)):2063-2076 doi:10.1002/pon.4794.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.

Loghavi S, Sui D, Wei P, et al.

Blood advances 2018; (2(15)):1807-1816 doi:10.1182/bloodadvances.2018019224.

Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Nazha A, Patnaik MM

Current hematologic malignancy reports 2018; (13(5)):341-347 doi:10.1007/s11899-018-0465-7.

Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.

Hunter AM, Zhang L, Padron E

Current treatment options in oncology 2018; (19(12)):67 doi:10.1007/s11864-018-0581-6.

Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.

Hu Z, Ramos CEB, Medeiros LJ, et al.

Human pathology 2019; (85()):290-298 doi:10.1016/j.humpath.2018.10.026.

Oncologist recommendation matters!-Predictors of psycho-oncological service uptake in oncology outpatients.

Frey Nascimento A, Tondorf T, Rothschild SI, et al.

Psycho-oncology 2019; (28(2)):351-357 doi:10.1002/pon.4948.

Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.

Benzarti S, Daskalakis M, Feller A, et al.

Cancer epidemiology 2019; (59()):51-57 doi:10.1016/j.canep.2019.01.003.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, et al.

American journal of hematology 2019; (94(7)):767-779 doi:10.1002/ajh.25488.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, et al.

Haematologica 2019; (104(10)):1935-1949 doi:10.3324/haematol.2019.222059.

Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.

Patnaik MM, Tefferi A

American journal of hematology 2020; (95(1)):97-115 doi:10.1002/ajh.25684.

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Coltro G, Mangaonkar AA, Lasho TL, et al.

Leukemia 2020; (34(5)):1407-1421 doi:10.1038/s41375-019-0690-7.

Autoimmune disease in CMML-the chicken or the egg?

Ambinder AJ, Miller J, DeZern AE

Best practice & research. Clinical haematology 2020; (33(2)):101136 doi:10.1016/j.beha.2019.101136.

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Moreno Berggren D, Kjellander M, Backlund E, et al.

British journal of haematology 2021; (192(3)):474-483 doi:10.1111/bjh.16790.

Update on CML-Like Disorders.

Cross NCP

Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S101-S102 doi:10.1016/S2152-2650(20)30477-8.

Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis.

Kunnumpurath A, Desikan SP, McClain C, Desikan R

Journal of investigative medicine high impact case reports 2020; (8()):2324709620966863 doi:10.1177/2324709620966863.

Atypical cutaneous histiocytic eruption in a patient with chronic myelomonocytic leukemia: A case report.

Li JJ, Talam S, Star P, Getta B

Journal of cutaneous pathology 2021; (48(5)):680-688 doi:10.1111/cup.13957.

Chronic myelomonocytic leukemia diagnosis and management.

Chan O, Renneville A, Padron E

Leukemia 2021; (35(6)):1552-1562 doi:10.1038/s41375-021-01207-3.

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.

Gagelmann N, Badbaran A, Beelen DW, et al.

Blood advances 2021; (5(6)):1760-1769 doi:10.1182/bloodadvances.2020003600.

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.

Tremblay D, Rippel N, Feld J, et al.

The oncologist 2021; (26(5)):406-421 doi:10.1002/onco.13769.

Mutations in chronic myelomonocytic leukemia and their prognostic relevance.

Jian J, Qiao Y, Li Y, et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021; (23(9)):1731-1742 doi:10.1007/s12094-021-02585-x.

Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.

Machherndl-Spandl S, Jäger E, Barna A, et al.

European journal of haematology 2021; (107(2)):265-274 doi:10.1111/ejh.13647.

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.

Carr RM, Vorobyev D, Lasho T, et al.

Nature communications 2021; (12(1)):2901 doi:10.1038/s41467-021-23186-w.

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.

Hunter AM, Newman H, Dezern AE, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(22)):6095-6105 doi:10.1158/1078-0432.CCR-21-0935.

Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.

Regnault A, Pompilus F, Ciesluk A, et al.

Journal of patient-reported outcomes 2021; (5(1)):60 doi:10.1186/s41687-021-00334-w.

Massive Right Atrial Thrombosis: Are You Brave Enough to Start Anticoagulation? A Case Report.

Bergonti M, Ascione C, Agostoni P, et al.

Frontiers in cardiovascular medicine 2021; (8()):688351 doi:10.3389/fcvm.2021.688351.

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.

Kuendgen A, Kasprzak A, Germing U

Frontiers in oncology 2021; (11()):778741 doi:10.3389/fonc.2021.778741.

Post-operative hyperleukocytosis and leukostasis as the initial presentation of chronic myelomonocytic leukemia: A case report and review of literature.

Gaur S, Philipovskiy A, Orazi A

Leukemia research reports 2021; (16()):100283 doi:10.1016/j.lrr.2021.100283.

Leukaemia cutis as a specific skin involvement in chronic myelomonocytic leukaemia and review of the literature: Acknowledgments.

Qiao Y, Jian J, Deng L, et al.

Translational cancer research 2020; (9(8)):4988-4998 doi:10.21037/tcr-19-2882.

Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report.

Pelkey LJ, Graham DM, Zakem MH, Muza-Moons MM

Cureus 2022; (14(2)):e22422 doi:10.7759/cureus.22422.

How I diagnose and treat chronic myelomonocytic leukemia.

Patnaik MM

Haematologica 2022; (107(7)):1503-1517 doi:10.3324/haematol.2021.279500.

The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation.

Gundabolu K, Dave BJ, Alvares CJ, et al.

Case reports in genetics 2022; (2022()):6977041 doi:10.1155/2022/6977041.

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.

Triguero A, Xicoy B, Zamora L, et al.

Leukemia research 2022; (116()):106836 doi:10.1016/j.leukres.2022.106836.

A Case of Chronic Myelomonocytic Leukemia Unmasked After Receiving J&J COVID-19 Vaccine.

Veeraballi S, Patel A, Are G, et al.

Cureus 2022; (14(6)):e26070 doi:10.7759/cureus.26070.

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Symeonidis A, Chondropoulos S, Verigou E, et al.

Frontiers in oncology 2022; (12()):884723 doi:10.3389/fonc.2022.884723.

Cancer patients' experiences and preferences when receiving bad news: a qualitative study.

Krieger T, Salm S, Dresen A, Cecon N

Journal of cancer research and clinical oncology 2023; (149(7)):3859-3870 doi:10.1007/s00432-022-04311-8.

Severe electrolyte derangements from lysozymuria in acute myeloid leukemia.

Pérez-Pinzón J, Olin RL, Banerjee R

EJHaem 2022; (3(3)):1018-1020 doi:10.1002/jha2.464.

Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.

Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, et al.

Cancers 2022; (14(17)) doi:10.3390/cancers14174107.

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Moyo TK, Mendler JH, Itzykson R, et al.

BMC cancer 2022; (22(1)):1013 doi:10.1186/s12885-022-10073-w.

Srsf2P95H/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice.

Xu JJ, Chalk AM, Wall M, et al.

Leukemia 2022; (36(12)):2883-2893 doi:10.1038/s41375-022-01727-6.

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Itzykson R, Santini V, Thepot S, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(10)):1888-1897 doi:10.1200/JCO.22.00437.

A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.

Bazinet A, Darbaniyan F, Kadia TM, et al.

Cancer 2023; (129(4)):560-568 doi:10.1002/cncr.34564.

CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.

Guastafierro V, Ubezio M, Manes N, et al.

Leukemia & lymphoma 2023; (64(9)):1566-1573 doi:10.1080/10428194.2023.2227750.

Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy.

Kudose S, Cossey LN, Canetta PA, et al.

Kidney international reports 2023; (8(8)):1585-1595 doi:10.1016/j.ekir.2023.05.007.

Germline CSF3R Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms.

Bochicchio MT, Micucci G, Asioli S, et al.

International journal of molecular sciences 2023; (24(22)) doi:10.3390/ijms242216021.

Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.

Patnaik MM, Tefferi A

American journal of hematology 2024; (99(6)):1142-1165 doi:10.1002/ajh.27271.

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

Onida F, Gagelmann N, Chalandon Y, et al.

Blood 2024; (143(22)):2227-2244 doi:10.1182/blood.2023023476.

Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis.

Haddad FG, Sasaki K, Senapati J, et al.

JCO oncology practice 2024; (20(12)):1637-1644 doi:10.1200/OP.24.00027.

Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison.

Kao HW, Kuo MC, Ou CW, et al.

The Journal of pathology 2025; (265(4)):437-447 doi:10.1002/path.6396.

Review of Psychological Interventions in Oncology: Current Trends and Future Directions.

Anghel T, Melania BL, Costea I, et al.

Medicina (Kaunas, Lithuania) 2025; (61(2)) doi:10.3390/medicina61020279.

Chronic Myelomonocytic Leukemia (CMML) as a Rare Cause of Spontaneous Atraumatic Splenic Rupture in a 65-Year-Old Male.

Sabbagh MN, Hoerdeman B, Hooshyar R, Ejeh I

Cureus 2025; (17(3)):e80357 doi:10.7759/cureus.80357.

Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.

Aguirre LE, Ball S, Jain A, et al.

Clinical lymphoma, myeloma & leukemia 2025; (25(9)):661-671 doi:10.1016/j.clml.2025.03.016.

Rare cases of atraumatic splenic rupture managed conservatively in patients with myeloid neoplasms: a report of two cases and literature review.

Chen M, Jiang M, Zhang W, et al.

Chinese clinical oncology 2025; (14(2)):21 doi:10.21037/cco-24-122.

Myeloid Neoplasms With Oligomonocytosis Exhibit Heterogenous Pathologic and Genetic Features.

Baloda V, Al Amri R, Patwardhan PP, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(10)):100823 doi:10.1016/j.modpat.2025.100823.

Contemporary CMML Risk Stratification and Management.

Sastow D, Syal A, Tremblay D

Current hematologic malignancy reports 2025; (20(1)):8 doi:10.1007/s11899-025-00753-2.

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.

Montalban-Bravo G, Loghavi S, Li Z, et al.

Blood advances 2025; (9(19)):5105-5117 doi:10.1182/bloodadvances.2025016529.

Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in cancer patients: A randomized controlled trial.

Betz LT, Rischer KM, Jacob GA, et al.

Journal of health psychology 2026; (31(3)):1136-1151 doi:10.1177/13591053251356885.

A comparative assessment of molecular-based prognostic models in CMML.

Aguirre LE, Al Ali N, Ball S, et al.

Blood neoplasia 2025; (2(4)):100116 doi:10.1016/j.bneo.2025.100116.

Approach to hyperleukocytosis and leukostasis-inpatient management strategies.

Baral MR, Bhandari S

Journal of hospital medicine 2026; (21(5)):534-538 doi:10.1002/jhm.70199.

Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case-control study.

Cioni P, Nguyen Y, Rohmer J, et al.

Rheumatology (Oxford, England) 2026; (65(2)) doi:10.1093/rheumatology/keaf685.

Impact of concurrent autoimmune conditions on clinical outcomes and leukaemic transformation in chronic myelomonocytic leukaemia.

Rungjirajittranon T, Ponvilawan B, Sukpanichnant S, Owattanapanich W

Journal of clinical pathology 2026; (79(5)):315-324 doi:10.1136/jcp-2025-210517.

[How I diagnose and treat chronic myelomonocytic leukemia].

Xiao ZJ

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2026; (47(2)):117-122 doi:10.3760/cma.j.cn121090-20251217-00597.

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Lanino L, Hunter AM, Gagelmann N, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; (44(17)):1608-1623 doi:10.1200/JCO-25-02116.